GSK meningitis vaccine shines in phase 3 trials

12 May 2023
www.pharmamanufacturing.com
Phase 3Drug ApprovalVaccineClinical Result
GSK revealed this week that its 5-in-1 meningitis vaccine — MenABCWY— shined in phase 3 trials. If approved, the vaccine would provide the most coverage against the infectious disease yet.
The vaccine was found to be as effective and have a similar safety profile as two doses of Bexsero and one dose of Menveo for five different Neisseria meningitidis serogroups (A, B, C, W, and Y) in individuals aged 10-25 years.
In a separate phase 3 trial, GSK’s MenABCWY also demonstrated its ability to provide immunological protection against a panel of 110 different meningococcal serogroup B invasive strains, which make up 95% of strains found in the US.
Bexsero and Menveo — both made by GSK — are immunizations administered to protect against specific types of meningococcal ailments. Bexsero vaccine is intended to work against meningococcal group B bacteria, whereas Menveo vaccine targets meningococcal groups A, C, W-135, and Y bacteria. These two vaccines are recommended for specific age groups, particularly adolescents and young adults, who might be at greater risk of contracting meningococcal disease.
In January 2013, Bexsero was approved by the European Commission for use in individuals from 2 months of age and older, making it the first broad coverage vaccine to receive a regulatory approval to help protect against meningitis B.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.